← Eichor
Condition: Stage Ii Iii Non Small Cell Lung Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Stage Ii Iii Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
NA · 4 location(s) · Thomas Jefferson University · NCT05502523Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Phase N/A · 1 location(s) · AIO-Studien-gGmbH · NCT02622581Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03872661Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stag
Phase 2 · 25 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06656598A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
NA · 1 location(s) · All India Institute of Medical Sciences · NCT07565987Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell
Phase 1/Phase 2 · 9 location(s) · National Cancer Institute (NCI) · NCT07012031To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mut
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT04853342PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
NA · 2 location(s) · University of Utah · NCT06945484Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
Phase N/A · 10 location(s) · Shanghai Chest Hospital · NCT07528066Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Vestre Viken Hospital Trust · NCT05344209A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Sma
Phase N/A · 1 location(s) · Yonsei University · NCT06907160Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell L
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT05487391Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Phase 2 · 20 location(s) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · NCT06552234A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
NA · 1 location(s) · Mayo Clinic · NCT06122064A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Phase 3 · 7 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04316364Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage I
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07410975Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Phase 3 · 2 location(s) · Hunan Province Tumor Hospital · NCT07251582A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed No
Phase 3 · 35 location(s) · ETOP IBCSG Partners Foundation · NCT06931717A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT05501665Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for L
Phase 2/Phase 3 · 261 location(s) · BioNTech SE · NCT06712316Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung C
Phase 2 · 1 location(s) · Fondazione Ricerca Traslazionale · NCT05568212Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Local
Phase 1/Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07632365Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuv
Phase 2 · 1 location(s) · Wen-zhao ZHONG · NCT07039656Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cel
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT03948100RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
Phase N/A · 10 location(s) · Shanghai Chest Hospital · NCT07541521Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Phase 2 · 2 location(s) · Emory University · NCT06731270
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.